Macque

马克

• 批准号: 8516869
• 负责人: Francois J Villinger
• 金额: $ 135.62万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516869
• 关键词: AIDS Vaccines; Adjuvant; Adult; Age; Agonist; Alleles; Animal Model; Animals; Antibodies; Antibody Affinity; Antibody Formation; Antigens; Arts; Autopsy; B-Cell Development; B-Lymphocytes; Binding; Biological Preservation; Biopsy; Blood; Breeding; CD4 Positive T Lymphocytes; Caring; Cells; Cellular biology; Clinical; Clinical Chemistry; Collection; Communication; Control Animal; DNA; Development; Diagnostic; Dose; Ensure; Euthanasia; Evaluation; Experimental Designs; Female; Future; Gender; Goals; Granulocyte-Macrophage Colony-Stimulating Factor; HIV; HIV Infections; HIV vaccine; Helper-Inducer T-Lymphocyte; Hematology; Histologic; Immune; Immune response; Immunity; Immunization; Immunologics; In Vitro; Infection; Infection prevention; Influenza; Instruction; Investigation; Laboratories; Macaca; Macaca mulatta; Mediating; Modeling; Monitor; Monkeys; Mus; Organ; Pathogenicity; Pathologic; Performance; Physical Examination; Play; Pre-Clinical Model; Primates; Process; Proteins; Research; Research Personnel; Resources; Retroviridae; Route; SIV; SIV Vaccines; Saliva; Sampling; Services; Simian T-lymphotropic virus 1; Source; Specimen; Testing; Tissue Sample; Toll-like receptors; Vaccines; Vagina; Vaginal Douching; Viral; Viremia; Virus; animal care; design; environmental enrichment for laboratory animals; lymph nodes; neutralizing antibody; nonhuman primate; novel; plasmid DNA; prevent; programs; protective effect; rectal; research study; response; sample collection; success; targeted delivery; tissue processing; transmission process; vaccine development; vaccine efficacy

The long-range goal of this Program Project is to develop vaccine strategies against mucosal SIV (and HIV in the future) transmission, with a special focus on identifying local and systemic mechanisms leading to protective B cell development and antibody production. The objectives for the Primate Core are to provide the experimental animals and support services needed to facilitate the efficient completion of the aims outlined in Project 1, 2, 3 and 4. This will include the provision of retrovirus-free adult female rhesus macaques from the Yerkes rhesus macaque breeding colonies; immunizations using the various immunization platforms (Projects 1 and 2) sample collections (for all projects) and repeated low dose vaginal challenges with SIVsmE660. The Primate Core tasks also include daily monitoring ofthe experimental animals; periodic physical examinations with blood collections for immunologic and virologic evaluations and procurement/shipment of samples to the Program Project investigators; the performance of CBCs and laboratory analyses as needed; Perform euthanasia with sample collection and processing for Projects 3 and 4; and the performance of a basic gross and histologic necropsy evaluations of all experimental animals that die or are sacrificed during the course of this study. Provision of these resources and support services will facilitate the development and testing of novel AIDS vaccine concepts proposed in this Program Project. The Primate Core will play a key role in the development of a vaccine to prevent mucosal transmission and pathogenicity of SIV and HIV and the determination Of correlates of such protection. Vaccine efficacy will be evaluated by its ability to 1) prevent acquisition of infection (sterilizing immunity) or 2) significant control of viremia post-challenge and preservation of protective immune responses.

该计划项目的长期目标是开发针对粘膜SIV（以及未来的HIV）传播的疫苗策略，特别关注识别导致保护性B细胞发育和抗体产生的局部和全身机制。灵长类核心的目标是提供实验动物和支持服务，以促进有效完成项目1，2，3和4中概述的目标。 这将包括提供来自Yerkes恒河猴繁殖群的无逆转录病毒成年雌性恒河猴;使用各种免疫平台（项目1和2）进行免疫接种;样本采集（用于所有项目）和使用SIVsmE 660进行重复低剂量阴道激发。灵长类核心任务还包括日常监测实验动物;定期体检，采集血液用于免疫学和病毒学评价，并将样本采购/运送给计划项目研究人员;根据需要进行CBC和实验室分析;为项目3和4进行安乐死，采集和处理样本;以及对本研究过程中死亡或处死的所有实验动物进行基本大体和组织学尸检评价。 提供这些资源和支持服务将促进本计划项目中提出的新艾滋病疫苗概念的开发和测试。灵长类核心将在预防SIV和HIV的粘膜传播和致病性的疫苗开发以及确定这种保护的相关性方面发挥关键作用。疫苗有效性将通过其1）预防感染获得（灭菌免疫）或2）攻毒后显著控制病毒血症和保护性免疫应答的能力进行评价。